» Articles » PMID: 35270010

Difference in MiRNA Expression in Functioning and Silent Corticotroph Pituitary Adenomas Indicates the Role of MiRNA in the Regulation of Corticosteroid Receptors

Abstract

Corticotroph pituitary adenomas commonly cause Cushing's disease (CD), but some of them are clinically silent. The reason why they do not cause endocrinological symptoms remains unclear. We used data from small RNA sequencing in adenomas causing CD ( = 28) and silent ones ( = 20) to explore the role of miRNA in hormone secretion and clinical status of the tumors. By comparing miRNA profiles, we identified 19 miRNAs differentially expressed in clinically functioning and silent corticotroph adenomas. The analysis of their putative target genes indicates a role of miRNAs in regulation of the corticosteroid receptors expression. Adenomas causing CD have higher expression of hsa-miR-124-3p and hsa-miR-135-5p and lower expression of their target genes and . The role of hsa-miR-124-3p in the regulation of was further validated in vitro using AtT-20/D16v-F2 cells. The cells transfected with miR-124-3p mimics showed lower levels of glucocorticoid receptor expression than control cells while the interaction between miR-124-3p and 3' UTR was confirmed using luciferase reporter assay. The results indicate a relatively small difference in miRNA expression between clinically functioning and silent corticotroph pituitary adenomas. High expression of hsa-miR-124-3p in adenomas causing CD plays a role in the regulation of glucocorticoid receptor level and probably in reducing the effect of negative feedback mediated by corticosteroids.

Citing Articles

Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention.

Aboregela A Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):69-88.

PMID: 39102032 DOI: 10.1007/s00210-024-03347-6.


The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.

Kober P, Rusetska N, Mossakowska B, Maksymowicz M, Pekul M, Zielinski G Front Endocrinol (Lausanne). 2023; 14:1124646.

PMID: 37065760 PMC: 10090509. DOI: 10.3389/fendo.2023.1124646.


Recent advances in understanding and managing pituitary adenomas.

Markou M, Lavrentaki A, Ntali G Fac Rev. 2023; 12:6.

PMID: 36968144 PMC: 10032474. DOI: 10.12703/r/12-6.


Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma.

Wu W, Cao L, Jia Y, Xiao Y, Zhang X, Gui S Cells. 2022; 11(18).

PMID: 36139495 PMC: 9496700. DOI: 10.3390/cells11182920.


The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.

Regazzo D, Mondin A, Scaroni C, Occhi G, Barbot M Int J Mol Sci. 2022; 23(12).

PMID: 35742910 PMC: 9224504. DOI: 10.3390/ijms23126469.

References
1.
Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P . Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol. 2009; 160(6):1003-10. DOI: 10.1530/EJE-09-0098. View

2.
Benite-Ribeiro S, Rodrigues V, Machado M . Food intake in early life and epigenetic modifications of pro-opiomelanocortin expression in arcuate nucleus. Mol Biol Rep. 2021; 48(4):3773-3784. DOI: 10.1007/s11033-021-06340-x. View

3.
Knosp E, Steiner E, Kitz K, Matula C . Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993; 33(4):610-7; discussion 617-8. DOI: 10.1227/00006123-199310000-00008. View

4.
Zhang Z, Che X, Yang N, Bai Z, Wu Y, Zhao L . miR-135b-5p Promotes migration, invasion and EMT of pancreatic cancer cells by targeting NR3C2. Biomed Pharmacother. 2017; 96:1341-1348. DOI: 10.1016/j.biopha.2017.11.074. View

5.
Ledderose C, Mohnle P, Limbeck E, Schutz S, Weis F, Rink J . Corticosteroid resistance in sepsis is influenced by microRNA-124--induced downregulation of glucocorticoid receptor-α. Crit Care Med. 2012; 40(10):2745-53. DOI: 10.1097/CCM.0b013e31825b8ebc. View